Table 1 Baseline characteristics of study population before and after propensity score matching.

From: Influence of concomitant percutaneous transluminal angioplasty with percutaneous coronary intervention on clinical outcomes of stable lower extremity artery diseases

 

Before PSM

After PSM

PTA + PCI

PCI only

p value

PTA + PCI

PCI only

p value

SMD

N = 279

N = 6284

N = 279

N = 1385

Male

214 (76.7)

3749 (59.7)

 < 0.001

214 (76.7)

1089 (78.6)

0.527

− 0.042

Age (years)

70.8 ± 9.0

69.4 ± 10.0

0.011

70.8 ± 9.0

70.8 ± 9.4

0.998

 < 0.001

Income levels ≥ median

134 (48)

3146 (50.1)

0.546

134 (48)

663 (47.9)

0.999

− 0.003

BMI (kg/m2)

23.8 ± 2.4

24.6 ± 2.6

 < 0.001

23.8 ± 2.4

23.8 ± 2.4

0.989

0.001

WC (cm)

84.9 ± 6.5

85.6 ± 7.1

0.091

84.9 ± 6.5

85.1 ± 6.9

0.705

− 0.025

eGFR (mL/min/1.73m2)

70.4 ± 20.2

75.2 ± 23.7

 < 0.001

70.4 ± 20.2

70.3 ± 21.3

0.98

0.002

Index MI

51 (18.3)

1958 (31.2)

 < 0.001

51 (18.3)

250 (18.1)

0.996

− 0.005

Multi vessel CAD

53 (19)

1025 (16.3)

0.271

53 (19)

254 (18.3)

0.862

− 0.017

Procedural characteristics

Number of coronary stents

1.97 ± 0.31

1.97 ± 0.25

0.795

1.97 ± 0.31

1.97 ± 0.25

0.992

0.022

Number of PCI vessels

1.24 ± 0.53

1.18 ± 0.46

0.099

1.24 ± 0.53

1.21 ± 0.50

0.464

0.049

Number of peripheral stents

1.71 ± 0.48

0.00 ± 0.00

–

1.71 ± 0.48

0.00 ± 0.00

–

–

Types of PTA

     

–

–

Plain balloon angiography

58 (20.8)

0 (0.0)

 

58 (20.8)

0 (0.0)

  

Drug-eluting balloon

5 (1.8)

0 (0.0)

 

5 (1.8)

0 (0.0)

  

Stenting

189 (67.7)

0 (0.0)

 

189 (67.7)

0 (0.0)

  

Others

27 (9.7)

6284 (100.0)

 

27 (9.7)

1385 (100.0)

  

Types of PCI

  

0.233

  

0.435

− 0.071

Plain balloon angiography

16 (5.7)

258 (4.1)

 

16 (5.7)

60 (4.3)

  

Drug-eluting balloon

8 (2.9)

106 (1.7)

 

8 (2.9)

24 (1.7)

  

Stenting

250 (89.6)

5826 (92.7)

 

250 (89.6)

1277 (92.2)

  

Others

5 (1.8)

94 (1.5)

 

5 (1.8)

24 (1.7)

  

DAPT duration (months)*

7 [1, 20]

12 [3, 28]

 < 0.001

7 [1, 20]

10 [2, 26]

0.019

− 0.109

Medication

DAPT

233 (83.5)

5515 (87.8)

0.044

233 (83.5)

1195 (86.3)

0.265

− 0.079

Statin

238 (85.3)

5708 (90.8)

0.003

238 (85.3)

1240 (89.5)

0.052

− 0.131

Oral and coagulants

14 (5.0)

169 (2.7)

0.034

14 (5)

52 (3.8)

0.413

0.066

Charlson's comorbidity index

5.3 ± 2.4

4.8 ± 2.5

 < 0.001

5.3 ± 2.4

5.3 ± 2.7

0.889

0.009

 ≤ 3

75 (26.9)

2133 (33.9)

0.003

75 (26.9)

383 (27.6)

0.948

0.021

4–6

118 (42.3)

2716 (43.2)

 

118 (42.3)

587 (42.4)

  

 ≥ 7

86 (30.8)

1435 (22.8)

 

86 (30.8)

415 (30.0)

  

Comorbidities

Any history of bleeding

31 (11.1)

588 (9.4)

0.381

31 (11.1)

130 (9.4)

0.437

− 0.057

Peptic ulcer

48 (17.2)

1047 (16.7)

0.876

48 (17.2)

236 (17)

1.000

− 0.004

Chronic lung diseases

42 (15.1)

662 (10.5)

0.022

42 (15.1)

205 (14.8)

0.987

0.008

Connective tissue disease

4 (1.4)

59 (0.9)

0.606

4 (1.4)

12 (0.9)

0.583

0.052

Heart failure

101 (36.2)

1948 (31.0)

0.075

101 (36.2)

489 (35.3)

0.784

0.019

Hypertension

256 (91.8)

5746 (91.4)

0.939

256 (91.8)

1269 (91.6)

1.000

− 0.005

Diabetes

219 (78.5)

4549 (72.4)

0.030

219 (78.5)

1106 (79.9)

0.665

0.032

Myocardial infarction

79 (28.3)

2434 (38.7)

0.001

79 (28.3)

390 (28.2)

1.000

− 0.003

Peripheral artery diseases

146 (52.3)

4146 (66)

 < 0.001

146 (52.3)

733 (52.9)

0.908

0.012

Intracranial hemorrhage

4 (1.4)

63 (1.0)

0.533

4 (1.4)

17 (1.2)

0.768

0.019

Stroke or cerebral ischemia

107 (38.4)

1590 (25.3)

 < 0.0001

107 (38.4)

513 (37.0)

0.684

0.028

Hemiplegia

17 (6.1)

109 (1.7)

 < 0.001

17 (6.1)

59 (4.3)

0.238

− 0.095

Dementia

13 (4.7)

294 (4.7)

1.000

13 (4.7)

94 (6.8)

0.235

− 0.101

Chronic kidney diseases

40 (14.3)

491 (7.8)

 < 0.001

40 (14.3)

188 (13.6)

0.808

− 0.024

End-stage renal diseases

18 (6.5)

178 (2.8)

0.001

18 (6.5)

82 (5.9)

0.840

− 0.025

  1. Data are presented with the mean ± SD or N (%).
  2. PSM, propensity-score matching; PCI, percutaneous coronary intervention; PTA, Percutaneous transluminal angioplasty; BMI, body mass index; WC, waist circumference; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; DAPT, dual-antiplatelet therapy.
  3. *Variables with a skewed distribution are presented with the median [1st quartile value, 3rd quartile value].
Back to article page